Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches

Current Neurology and Neuroscience Reports

Volumn 11, Issue 2, 2011, Pages 131-138

  Shuster, Lynne T ^a   Faubion, Stephanie S ^a   Sood, Richa ^a   Casey, Petra M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bilateral oophorectomy; Estrogen; Estrogen withdrawal; Headache; Hormonal fluctuations; Hormonally related headaches; Ischemic stroke; Menopausal hormone therapy; Menopause; Menstrual migraine; Migraine; Oral contraceptives; Ovarian insufficiency; Perimenopause; Progesterone; Progestogen; Stroke; Surgical menopause; Transdermal estrogen

Indexed keywords

CONTRACEPTIVE AGENT; ESTRADIOL; ESTROGEN; ESTROGEN CONTAINING HORMONAL CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; TRIPHASIC CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

BLOOD CLOTTING; BRAIN ISCHEMIA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG USE; EARLY MENOPAUSE; ESTROGEN THERAPY; GALLBLADDER DISEASE; HEADACHE; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HORMONALLY RELATED HEADACHE; HORMONE BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MENOPAUSE RELATED DISORDER; MENSTRUAL MIGRAINE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NOMENCLATURE; OVARY FUNCTION; PERIMENOPAUSAL HEADACHE; POSTMENOPAUSAL MIGRAINE; POSTOPERATIVE COMPLICATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT;

CONTRACEPTIVES, ORAL; ESTRADIOL; FEMALE; HUMANS; MALE; MENOPAUSE; MENSTRUAL CYCLE; MIGRAINE DISORDERS; RISK FACTORS; STROKE;

EID: 79955875217     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0174-7     Document Type: Review

References (49)

1. Victor TW, Hu X, Campbell JC, et al.: Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30: 1065-1072, 2010. This paper provides important information on the prevalence of migraine in nearly 41,000 US men, women, and children. It provides new information on changes in migraine prevalence from childhood into adulthood, with interesting information on rates of change by age and sex.
2. Nappi RE, Sances G, Detaddei S, et al.: Hormonal management of migraine at menopause. Menopause Int 15: 82-86, 2009
3. Stewart WF, Wood C, Reed ML, et al.: Cumulative lifetime migraine incidence in women and men. Cephalalgia 28: 1170-1178, 2008
4. Silberstein SD: Headache and female hormones: what you need to know. Curr Opin Neurol 14: 323-333, 2001
5. MacGregor EA, Frith A, Ellis J, et al.: Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67: 2154-2158, 2006 (Pubitemid 46035468)
6. Loder E, Rizzoli P, Golub J: Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache 47: 329-340, 2007
7. Beckham JC, Krug LM, Penzien DB, et al.: The relationship of ovarian steroids, headache activity and menstrual distress: a pilot study with female migraineurs. Headache 32: 292-297, 1992
8. Martin VT, Wernke S, Mandell K, et al.: Defining the relationship between ovarian hormones and migraine headache. Headache 45: 1190-1201, 2005 (Pubitemid 350004908)
9. Martin VT, Behbehani M: Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis-part I. Headache 46: 3-23, 2006
10. Herzog AG: Neuroactive properties of reproductive steroids. Headache 47 Suppl 2: S68-78, 2007
11. Hart EC, Charkoudian N, Miller VM: Sex, Hormones and Neuroeffector Mechanisms. Acta Physiol (Oxf)
12. Zacur HA: Hormonal changes throughout life in women. Headache 46 Suppl 2: S49-54, 2006
13. Martin VT, Lipton RB: Epidemiology and biology of menstrual migraine. Headache 48(Suppl 3): S124-130, 2008
14. Pinkerman B, Holroyd K: Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine. Cephalalgia 30: 1187-1194, 2010.
15. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 Suppl 1: 9-160, 2004
16. Silberstein SD, Merriam GR: Estrogens, progestins, and headache. Neurology 41: 786-793, 1991
17. Hudson JI, Goldenberg DL, Pope HG, Jr., et al.: Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 92: 363-367, 1992
18. Calhoun AH, Hutchinson S: Hormonal therapies for menstrual migraine. Curr Pain Headache Rep 13: 381-385, 2009
19. Somerville BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 22: 355-365, 1972
20. ACOG Practice Bulletin No. 110: Noncontraceptive Uses of Hormonal Contraceptives. Obstet Gynecol 2010, 115: 206-218. This is a clinically focused summary from the American College of Obstetricians and Gynecologists regarding the use of hormonal contraceptives for menstrual cycle regulation, premenstrual syndrome, migraine, and other conditions.
21. Menopause Practice: A Clinician's Guide. The North American Menopause Society, 2007
22. MacGregor EA: Estrogen replacement and migraine. Maturitas 63: 51-55, 2009. This is a very useful, clinically focused summary of the literature on estrogen therapy and migraine.
23. Loder EW, Buse DC, Golub JR: Headache as a side effect of combination estrogen-progestin oral contraceptives: a systematic review. Am J Obstet Gynecol 193: 636-649, 2005 (Pubitemid 41261456)
24. Aegidius K, Zwart JA, Hagen K, et al.: Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology 66: 349-353, 2006 (Pubitemid 43739935)
25. Tozer BS, Boatwright EA, David PS, et al.: Prevention of migraine in women throughout the life span. Mayo Clin Proc 81: 1086-1091; quiz 1092, 2006
26. Sulak P, Willis S, Kuehl T, et al.: Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 47: 27-37, 2007 (Pubitemid 46096054)
27. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ: Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74: 100-103, 2006 (Pubitemid 44062466)
28. Neri I, Granella F, Nappi R, et al.: Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 17: 31-37, 1993
29. Shuster LT, Rhodes DJ, Gostout BS, et al.: Premature menopause or early menopause: long-term health consequences. Maturitas 65: 161-166
30. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17: 242-255, 2010. This is a pivotal summary of current findings regarding the benefits and risks of HT started around the time of menopause.
31. Santen RJ, Allred DC, Ardoin SP, et al.: Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 95: s1-s66, 2010. This is a comprehensive scientific summary of postmenopausal HT indications, uses, risks, and benefits, with meticulous grading of evidence. It is an integrated reference source providing an extensive amount of well-summarized cumulative data on the pros and cons of postmenopausal HT.
32. Kaunitz AM: Hormonal Contraception in Women of Older Reproductive Age. The New England Journal of Medicine: 1262-1270, 2008
33. Curtis KM, Mohllajee AP, Peterson HB: Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review. Contraception 73: 189-194, 2006 (Pubitemid 43087768)
34. Bousser MG, Conard J, Kittner S, et al.: Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. The International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy. Cephalalgia 20: 155-156, 2000 (Pubitemid 32269502)
35. Spector JT, Kahn SR, Jones MR, et al.: Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123: 612-624
36. Kurth T, Schurks M, Logroscino G, et al.: Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 337: a636, 2008
37. Loder EW, Buse DC, Golub JR: Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache 45: 224-231, 2005 (Pubitemid 40393212)
38. Davis PH: Use of oral contraceptives and postmenopausal hormone replacement: evidence on risk of stroke. Curr Treat Options Neurol 10: 468-474, 2008
39. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 107: 1453-1472, 2006
40. World Health Organization. Medical eligibility criteria for contraceptive use-4th ed. world Health Organization 2010, 2010
41. Massiou H, MacGregor EA: Evolution and treatment of migraine with oral contraceptives. Cephalalgia 20: 170-174, 2000 (Pubitemid 32269505)
42. Parker WH, Broder MS, Chang E, et al.: Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 113: 1027-1037, 2009
43. Lisabeth LD, Beiser AS, Brown DL, et al.: Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 40: 1044-1049, 2009
44. Baba Y, Ishikawa S, Amagi Y, et al.: Premature menopause is associated with increased risk of cerebral infarction in Japanese women. Menopause 17: 506-510
45. Rivera CM, Grossardt BR, Rhodes DJ, et al.: Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16: 15-23, 2009
46. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM: Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 113: 5-14, 2006
47. Sare GM, Gray LJ, Bath PM: Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29: 2031-2041, 2008
48. Renoux C, Dell'aniello S, Garbe E, Suissa S: Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 340: c2519
49. Shufelt C, Bairey-Merz C, Prentice R, Pettinger M, Manson J, Investigators ftWsHI: Low-dose estrogen and risk of cardiovascular events: findings from the WHI observational study. The North American Menopause Society 21st Annual Meeting, Chicago, IL.